News archives


OCTOBER - DECEMBER 17

JULY - SEPTEMBER 17

APRIL - JUNE 17

JANUARY - MARCH 17

OCTOBER - DECEMBER 16

JULY - SEPTEMBER 16

APRIL - JUNE 16

JANUARY - MARCH 16

OCTOBER - DECEMBER 15

JULY - SEPTEMBER 15

APRIL - JUNE 15

JANUARY - MARCH 15

OCTOBER - DECEMBER 14

JULY - SEPTEMBER 14

APRIL - JUNE 14

JANUARY - MARCH 14

OCTOBER - DECEMBER 13

JULY - SEPTEMBER 13

APRIL - JUNE 13

JANUARY - MARCH 13

OCTOBER - DECEMBER 12

JULY - SEPTEMBER 12

APRIL - JUNE 12

JANUARY - MARCH 12

OCTOBER - DECEMBER 11

JULY - SEPTEMBER 11

APRIL - JUNE 11

JANUARY - MARCH 11

OCTOBER - DECEMBER 10

JULY - SEPTEMBER 10

APRIL - JUNE 10

JANUARY - MARCH 10

OCTOBER - DECEMBER 09

JULY - SEPTEMBER 09

APRIL - JUNE 09

JANUARY - MARCH 09

OCTOBER - DECEMBER 08

JULY - SEPTEMBER 08

APRIL - JUNE 08

JANUARY - MARCH 08

OCTOBER - DECEMBER 07

JULY - SEPTEMBER 07

APRIL - JUNE 07

JANUARY - MARCH 07

 
  current news   Press   selected story    
     
  18 August 2014  
  Viral small T oncoproteins transform cells by alleviating hippo pathway-mediated inhibition of the YAP proto-oncogene
 
 



Authors
Hung Thanh Nguyen1,*, Xin Hong2,3*, Sam Tan1, Qingfeng Chen2,4, Lifang Chan1, Marc Fivaz1,5, Stephen M. Cohen2,3 & P. Mathijs Voorhoeve1.

1     Duke-NUS Graduate Medical School, 8 College Rd, Singapore,169857
2     Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore, 138673
3     Department of Biological Sciences, National University of Singapore, 117543
4     Department of Microbiology, National University of Singapore, 117545
5     Department of Physiology, National University of Singapore, 117597

*   Equal contribution

Published in Cell Reports on 31 July 2014.

Abstract

Primary human cells can be transformed into tumor cells by a defined set of genetic alterations including telomerase, oncogenic RasV12 and the tumor suppressors p53 and pRb. SV40 Small T (ST) is required for anchorage-independent growth in vitro and in vivo. Here, we identify the Hippo tumor suppressor pathway as a critical target of ST in cellular transformation. We report that ST uncouples YAP from the inhibitory activity of the Hippo pathway through PAK1-mediated inactivation of NF2. Membrane-tethered activated PAK is sufficient to bypass the requirement for Small T in anchorage-independent growth. PAK acts via YAP to mediate the transforming effects of Small T. Activation of endogenous YAP mediates the transforming effects of Small T, and is sufficient to bypass Small T in anchorage independent growth and xenograft tumor formation. Our findings uncover the Hippo tumor suppressor pathway as a final gatekeeper to transformation and tumorigenesis of primary cells.

  • Small T acts via PAK to inactivate NF2 tumor suppressor thereby activating YAP
  • PAK acts downstream of ST in cellular transformation
  • YAP is required for anchorage independent growth caused by Small T and active PAK1

For more information on Stephen COHEN’s laboratory, please click here.